Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of isolated protein binding antigen psma and its use

A technology for binding proteins and chimeric antigen receptors, applied in the field of biomedicine, can solve the problems of unknown epitope information, lack of cross-germline cross-reactivity, etc., and achieve the effect of relieving and/or treating tumors

Active Publication Date: 2020-12-25
NONA BIOSCIENCES CO LTD
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Despite progress on PSMA targets, PSMA antibodies have many deficiencies that cannot be ignored, such as unknown epitope information for antibody binding, lack of data on cross-species cross-reactivity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of isolated protein binding antigen psma and its use
  • A kind of isolated protein binding antigen psma and its use
  • A kind of isolated protein binding antigen psma and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0181] Example 1. Generation and screening of monoclonal hybridoma cells

[0182] 1.1 Preparation of CHO-K1 / cyno PSMA cell stable transfection line

[0183] Lentiviral particles (Jikai Gene, cat#LVCON335) packaged with the nucleic acid sequence encoding cynomolgus monkey PSMA (the Genbank accession number of the corresponding cynomolgus PSMA amino acid sequence is XP_ 005579379) were packed with M.O.I.=100 ((M.O.I. = (slow Virus particle titer * volume) / number of infected cells) to infect CHO-K1 cells (ATCC, cat# CCL-61). Cells after 48 hours of infection were subcultured at a ratio of 1:10 with 8 µg / ml Screening resistance and F2K medium with 10% (w / v) fetal bovine serum for about 1 week until CHO-K1 in the uninfected control group was screened for resistance and killed, while CHO-K1 cells in the infected group still survived. CHO-K1 cells in the lentivirus infection group were digested and limitedly diluted to 0.5 cells per well in a 96-well plate, and then cultured with ...

Embodiment 2

[0190] Example 2. Sequencing, Expression and Purification of Monoclonal PSMA Antibody

[0191] The monoclonal PSMA antibody screened in Example 1 was sequenced, and the amino acid sequence is shown in Table 1.

[0192] Table 1. Sequencing results of monoclonal PSMA antibodies

[0193]

[0194] The heavy chain variable region sequence of the above monoclonal PSMA antibody was subcloned into pTT5 expression vector containing signal peptide and human heavy chain IgG1 constant region (SEQ ID NO: 19). The light chain variable region sequence of the monoclonal PSMA antibody was subcloned into an expression vector containing the signal peptide and the human antibody light chain kappa constant region (SEQ ID NO: 20). After the recombinant plasmid was confirmed by sequencing, the plasmid was extracted with a large extraction kit (Macherey-Nagel, NucleoBond® Xtra Midi) to improve the purity and quality of the recombinant plasmid, and the plasmid was filtered through a 0.22 µm filter...

Embodiment 3

[0200] Example 3. Binding Ability of Monoclonal PSMA Antibody to Cell Surface PSMA

[0201] HEK293T cells overexpressing human PSMA (HEK293T / human PSMA, Kangyuan Bochuang, cat#KC-1005) or CHO-K1 cells overexpressing cynomolgus PSMA (CHO-K1 / cyno PSMA) or overexpressing human PSMA Tumor cells (LNCAP) were cultured and expanded in T-75 culture flasks. After reaching 90% confluency, the medium was aspirated and the cells were washed twice with PBS. Cells were treated with trypsin (Invitrogen, cat#15050065) for about 1 minute, and the trypsin was neutralized with culture medium. Then the cells were washed twice with PBS, the cell count was determined, and the cells were resuspended in PBS to 2×10 6 cells / ml. Add 100 µl of cell suspension to each well of a 96-well V-plate. Incubate with different concentrations of purified PSMA antibody or isotype control antibody for 1 hour on ice. Cells were washed twice with PBS and incubated with goat anti-human (H+L)-Alexa Fluor 647 (Life t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The application provides a separated antigen binding protein. The separated antigen binding protein contains HCDR1, HCDR2 and HCDR3 in VH of which the amino acid sequence is as shown in SEQID NO:15, and contains LCDR1, LCDR2 and LCDR3 of VL of which the amino acid sequence is as shown in SEQID NO:16. The application also provides a chimeric antigen receptor containing the separated antigen bindingprotein, an immune coupling substance containing the separated antigen binding protein, nucleic acid coding the separated antigen binding protein, a carrier containing the separated antigen binding protein, a cell containing the nucleic acid or the carrier, a method for preparing the separated antigen binding protein, and the purpose of the separated antigen binding protein.

Description

technical field [0001] This application relates to the field of biomedicine, in particular to an isolated protein that binds to the antigen PSMA and its application. Background technique [0002] For men, prostate cancer is the most commonly diagnosed cancer and the third leading cause of death from cancer. According to statistics, 160,000 patients were diagnosed with this tumor in 2017 and 26,000 died (Siegel RL et al. , (2017) CA Cancer J Clin . 67:7–30). Patients with localized cancer are usually treated with surgery or radiotherapy (Walsh PC et al ., (2007) N Engl J Med . 357:2696–705). However, 20-40% of patients who undergo radical prostatectomy, and 30-50% of those who undergo radiotherapy experience recurrence (Paller CJ et al. , (2013) Clin Adv Hematol Oncol . 11:14–23). Standard therapy for metastatic cancer is usually androgen blockade, either by bilateral orchiectomy or chemical castration (eg, administration of luteinizing hormone receptor (LHR)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/30C07K19/00C12N15/13C12N15/62C12N15/85C12N5/10G01N33/68G01N33/574A61K39/395A61P35/00
CPCA61K2039/505A61P35/00C07K16/3069C07K2317/565C07K2319/00C12N5/0636C12N15/85C12N2510/00G01N33/57434G01N33/57484G01N33/68
Inventor 黄冰何云戎一平
Owner NONA BIOSCIENCES CO LTD